Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

Ibrutinib and other targeted inhibitors of B-cell receptor signaling achieve impressive clinical results for patients with chronic lymphocytic leukemia (CLL). A treatment-induced rise in absolute lymphocyte count (ALC) has emerged as a class effect of kinase inhibitors in CLL and warrants further in...

Full description

Bibliographic Details
Main Authors: Herman, Sarah E. M., Niemann, Carsten U., Farooqui, Mohammed, Jones, Jade, Mustafa, Rashida Z., Lipsky, Andrew, Saba, Nakhle, Martyr, Sabrina, Soto, Susan, Valdez, Janet, Gyamfi, Jennifer A., Maric, Irina, Calvo, Katherine R., Pedersen, Lone B., Geisler, Christian H., Liu, Delong, Marti, Gerald E., Aue, Georg, Wiestner, Adrian
Format: Online
Language:English
Published: 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185271/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185271/

Similar Items